Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
Level 1 Starter
Monthly Subscription
for only
|
|
VAT not included
|
|
After Hours Last Trade |
Last $ 1.84 ◊ 0.00 (0.00%) | |
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Aclaris Therapeutics Inc | ACRS | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| -0.13 | -6.6% | 1.84 | 2.00 | 1.80 | 1.97 | 1.97 | 19:59:37 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 0.50 | 1.85 | 1.35 | 72.97% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 2,113 | 546,785 | $ 1.92 | $ 1,047,871 | 702,629 | 0.74 - 7.69 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 17:25:26 | 55 | $ 1.85 | USD |
Aclaris Therapeutics Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 76.15M | 41.39M | $ -132.74M | -4.04 | - | 39.61M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Aclaris Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ACRS Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.27 | 2.65 | 1.80 | 2.11 | 2,179,385 | -0.43 | -18.94% |
| 1 Month | 1.77 | 2.65 | 1.75 | 2.03 | 915,152 | 0.07 | 3.95% |
| 3 Months | 1.86 | 2.65 | 1.47 | 1.87 | 793,130 | -0.02 | -1.08% |
| 6 Months | 2.21 | 2.65 | 0.74 | 1.50 | 1,333,369 | -0.37 | -16.74% |
| 1 Year | 6.43 | 7.69 | 0.74 | 2.55 | 968,338 | -4.59 | -71.38% |
| 3 Years | 28.60 | 33.25 | 0.74 | 9.33 | 535,528 | -26.76 | -93.57% |
| 5 Years | 11.94 | 33.88 | 0.74 | 10.35 | 406,173 | -10.10 | -84.59% |
Aclaris Therapeutics Description
| Aclaris Therapeutics Inc is a clinical-stage specialty pharmaceutical company which operates in United States. It focuses on identifying, developing and commercializing differentiated drugs to address significant unmet needs in dermatology. The company holds a drug candidate, A-101 Topical Solution which is a proprietary high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis (SK) a common non-malignant skin tumor. Its pipeline of drug candidates includes A-101 as a Topical Solution for treatment of SK, common warts; A-102 as a gel dosage form for treatment of SK and warts and A-201 and A-301 as an oral and topical formulation for treatment of autoimmune dermatologic respectively. |
